Multikinase inhibitors with anti‐FGFR activity often simultaneously target VEGF/VEGFR signaling, thereby collaboratively interfering with tumor angiogenesis and regulating the immune microenvironment.19 The gene discussed is KDR; the disease is neoplasm.